Table 2.

Characteristics of immunocompromised and non- immunocompromised IPA patients

	IPA patients (n = 254)	Immunocompromised (n = 66)	non- immunocompromised (n = 188)	p value
Demographics
Sex, male (%)	179 (70.5%)	42 (72.9%)	137 (63.6%)	0.157
Age, yrs.	61 ± 15	54 ± 15	64 ± 15	< 0.001*
Admission data
Diagnostic time, days (IQR)	20 (12 ~ 30)	18 (10 ~ 36)	20 (12 ~ 30)	0.461
Mechanical ventilation	51 (20.1%)	18 (27.1%)	33 (17.6%)	0.09
ICU admission	62 (24.4%)	22 (33.3%)	40 (21.3%)	0.05
Poor prognosis	57 (22.4%)	23 (34.8%)	34 (18.1%)	0.005*
Symptoms
fever	188 (74.0%)	44 (66.7%)	144 (76.6%)	0.114
productive cough	226 (89.0%)	53 (80.3%)	173 (92.0%)	0.009*
hemoptysis	38 (15.0%)	8 (12.1%)	30 (16.0%)	0.452
dyspnea	158 (62.2%)	37 (56.1%)	121 (64.4%)	0.231
chest pain	15 (5.9%)	3 (4.5%)	12 (6.4%)	0.586
Diagnostics
Histopathology	46	10	36
Lung tissue culture of positive	29	1	28
Culture of LRT preformed	254	66	188
LRT culture positive	196 (77.1%)	50 (75.7%)	146 (77.7%)	0.553
Serum GM preformed	107	19	88
Serum GM positive	59 (55.1%)	12 (63.1%)	47 (53.4%)	0.388
BALF GM preformed	38	7	31
BALF GM positive	36 (94.7%)	7 (100%)	29 (93.4%)	0.490

GM Galactomannan

BALF Bronchoalveolar lavage fluid

LRT Low respiratory tract

note: * p<0.05